TATA Health International Holdings Limited (Stock code: 1255) recently disclosed key findings from an independent internal control review conducted by Valplus Consulting Limited, covering corporate and subsidiary-level processes as well as financial reporting and disclosure procedures. The review identified several areas for improvement, including alignment of governance policies with relevant rules, the need to appoint an independent non-executive director with accounting or financial expertise, the establishment of a standardized subsidiary financial reporting policy, additional senior finance capacity, and enhanced governance for loan management.

In response, TATA Health International Holdings Limited updated and circulated revised governance, reporting, and loan management policies to its Board, senior management, and finance teams. The company also filled key leadership roles, including appointing a new Group chief financial officer. The audit committee and the Board have acknowledged that the measures taken address identified internal control issues, strengthening the company’s ability to meet regulatory obligations and enhance overall operational oversight.

Trading in the company’s shares on The Stock Exchange of Hong Kong Limited remains suspended pending fulfillment of relevant resumption guidance. The Board has pledged to continue monitoring the effectiveness of these enhancements and will provide further updates as needed.